세계의 스마트 필 시장 예측(-2030년) : 치료 분야별, 용도별, 적응 질환별, 최종사용자별, 지역별

The global smart pills market is experiencing significant growth in 2024, driven by the technological advancements in capsule endoscopy and the growing demand for non-invasive diagnostic monitoring devices. The market is projected to reach reach USD 1.30 billion by 2030 from USD 0.69 billion in 2024, at a CAGR of 11.2% during the forecast period. According to the American Cancer Society (ACS), in 2024, there were 1,52,810 new cases of colorectal cancer (CRC) comprising, 81,540 will be in men and 71,270 in women. Additionally, 1,06,590 of the cases will be colon cancer, while 46,220 will be rectal cancer. CRC remains the second leading cause of cancer-related deaths in the US with an estimated 53,010 deaths in 2024, showing a slight increase from last year's projected 52,550. Thus, the high incidence of colon cancer are expected to increase the demand for capsule endoscopes for colon cancer screening.

"The small bowel tumor segment is projected to grow at the highest CAGR during the forecast period."

Based on disease indication, the market for smart pills is divided into segments for crohn's disease, small bowel tumors, occult GI bleeding, celiac disease, and other disease indications. The small bowel tumor is expected to grow at the highest CAGR during the forecast period due to factors, such as advancements in sensor technology, growing emphasis on patient convenience, rising need for early tumor diagnosis and proper treatment that are expected to drive the adoption of smart pills in the coming years.

"The large intestine accounted for the second largest share of the market during the forecast period in 2023, by target area. "

By target area, the smart pills market is broadly segmented into, small intestine, large intestine, esophagus, and stomach. In 2023, the large intestine target area accounted for the second largest share of smart pills market. Factors such as rising cases of colorectal cancer and requirement for applicable screening, diagnosis, and examining of inflammatory bowel diseases and other gastrointestinal diseases. The growing cases of colorectal cancer & colon cancer have contributed to the rising adoption of smart pills in large intestine as smart pills can reach areas of the colon that may be difficult to visualize with traditional methods.

By region, Europe hold the second largest share of the smart pills market in 2023

Europe accounted for the second largest share of the smart pills market in 2023. Factors such as increase in ageing population and improved utilization of capsule endoscopy for gastrointestinal (GI) bleeding are driving the European smart pills market. According to the guidelines of the European Society of Gastrointestinal Endoscopy (ESGE), small-bowel video capsule endoscopy is recommended as the initial examination for patients with unclear gastrointestinal bleeding. The endorsement of capsule endoscopy by the ESGE guidelines specifies a uniform approach for healthcare professionals, improving the quality of care provided to patients. As a result, the expanding demand for smart pills and other related technologies is driven by the growing use of capsule endoscopy for GI bleeding.

The break up of the profile of primary participants in the smart pills market:

• By Company Type: Tier 1- 40%, Tier 2- 35%, and Tier 25%
• By Designation: C-level Executives- 50%, Directors- 40% , and Others- 10%.
• By Region: North America- 45%, Europe- 30%, Asia Pacific- 20%, Latin America- 3%, and Middle East & Africa- 2%.

Key players in the Smart pills market

The key players operating in the smart pills market include Medtronic (US), Olympus Corporation (Japan), CapsoVision,Inc. (US), IntroMedic (South Korea), ANX Robotics (US), Shenzhen Jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (Group) (China), etectrx (US), Check-Cap (Israel), BodyCap (France) ,and Shangxian Minimal Invasive Inc (China).

Research Coverage:

The report analyzes the smart pills market and aims at estimating the market size and future growth potential of this market based on various segments such as application (capsule endoscopy,patient monitoring, and targeted drug delivery), target area (small intestine,large intestine, esophagus & stomach), disease indication (crohn's disease, occult GI bleeding, small bowel tumor, celiac disease, & other disease conditions), end user (hospitals, diagnostic centers, outpatient settings, & other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The report also includes a product portfolio matrix of various smart pills products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

• Analysis of key drivers (rising demand for noninvasive diagnostic monitoring devices, technological advancements in capsule endoscopy, increasing incidence of colon cancer), restraints (high costs & technical limitations associated with accuracy of smart pills), opportunities (continuous innovation in sensor technology, wireless communication and rising need for rapid drug delivery development) and challenges (patient privacy concerns, shortage of skilled personnel).
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the smart pills market
• Market Development: Comprehensive information about lucrative markets - the report analyses the smart pills market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the smart pills market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of Medtronic (US), Olympus Corporation (Japan), CapsoVision,Inc. (US), IntroMedic (South Korea), ANX Robotics (US), Shenzhen jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (Group) (China), etectrx (US), Check-Cap (Israel), BodyCap (France) , and Shangxian Minimal Invasive Inc (China) in the smart pills market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Objectives of primary research
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Insights from primary experts
  • 2.1.3 MARKET SIZE ESTIMATION
    • 2.1.3.1 Supply-side analysis
    • 2.1.3.2 Bottom-up approach (demand-side analysis)
    • 2.1.3.3 Top-down approach (parent market assessment)
• 2.2 DATA TRIANGULATION
• 2.3 STUDY ASSUMPTIONS
• 2.4 RISK ANALYSIS
• 2.5 RESEARCH LIMITATIONS
  • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.5.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 SMART PILLS MARKET OVERVIEW
• 4.2 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION AND COUNTRY, 2023
• 4.3 SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 SMART PILLS MARKET: REGIONAL MIX
• 4.5 SMART PILLS MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising demand for non-invasive diagnostic monitoring devices
    • 5.2.1.2 Technological advancements in capsule endoscopy
    • 5.2.1.3 Increasing incidence of colon cancer
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High R&D costs for technological developments and advancements
    • 5.2.2.2 Low accuracy and reliability of sensors and cameras in smart pills
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Innovations in sensor technologies and wireless communication
    • 5.2.3.2 Rising need for rapid drug delivery and development
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Increased patient privacy and data security concerns
    • 5.2.4.2 Shortage of skilled healthcare professionals
• 5.3 INDUSTRY TRENDS
  • 5.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGIES
  • 5.3.2 INTEGRATION WITH AI AND ML
  • 5.3.3 INTEGRATION WITH WEARABLE DEVICES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Wireless communication systems
    • 5.4.1.2 Sensor technologies
    • 5.4.1.3 Self-powered ingestible smart pills
    • 5.4.1.4 Adaptive frame rate technologies
    • 5.4.1.5 iMAG
    • 5.4.1.6 AI and ML
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Robotic technologies
    • 5.4.2.2 Data analytics
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 IoT
    • 5.4.3.2 Cloud computing
• 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.6 PIPELINE ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7.2 THREAT OF NEW ENTRANTS
  • 5.7.3 THREAT OF SUBSTITUTES
  • 5.7.4 BARGAINING POWER OF SUPPLIERS
  • 5.7.5 BARGAINING POWER OF BUYERS
• 5.8 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.8.2 KEY BUYING CRITERIA
• 5.9 ECOSYSTEM ANALYSIS
• 5.10 VALUE CHAIN ANALYSIS
• 5.11 TARIFF & REGULATORY ANALYSIS
  • 5.11.1 TARIFF DATA ANALYSIS
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11.3 REGULATORY LANDSCAPE
    • 5.11.3.1 North America
      • 5.11.3.1.1 US
    • 5.11.3.2 Europe
    • 5.11.3.3 Asia Pacific
      • 5.11.3.3.1 Japan
      • 5.11.3.3.2 China
      • 5.11.3.3.3 India
• 5.12 PRICING ANALYSIS
  • 5.12.1 AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER, 2023
  • 5.12.2 AVERAGE SELLING PRICE TREND FOR CAPSULE ENDOSCOPES, BY REGION, 2020-2023
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES
  • 5.13.2 DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES
  • 5.13.3 AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS
• 5.14 PATENT ANALYSIS
  • 5.14.1 PATENT PUBLICATION TRENDS FOR SMART PILLS
  • 5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.14.3 LIST OF KEY PATENTS
• 5.15 KEY CONFERENCES & EVENTS, 2025-2026
• 5.16 UNMET NEEDS & END-USER EXPECTATIONS
  • 5.16.1 UNMET NEEDS
  • 5.16.2 END-USER EXPECTATIONS
• 5.17 TRADE ANALYSIS
• 5.18 INVESTMENT & FUNDING SCENARIO
• 5.19 BUSINESS MODEL ANALYSIS
  • 5.19.1 DIRECT SALES TO HEALTHCARE PROVIDERS
  • 5.19.2 SUBSCRIPTION-BASED SOFTWARE AND DATA ANALYTICS SERVICES
• 5.20 IMPACT OF AI/GEN AI ON SMART PILLS MARKET
  • 5.20.1 KEY USE CASES
  • 5.20.2 CASE STUDIES OF AI/GEN AI IMPLEMENTATION
    • 5.20.2.1 CapsoCam SV-1 Versus PillCam SB3 to detect obscure gastrointestinal bleeding
    • 5.20.2.2 AARDEX Group partnered with etectRx, Inc. to track medication-taking behaviors
  • 5.20.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.20.3.1 AI in endoscopy
    • 5.20.3.2 Wearable devices
    • 5.20.3.3 Digital healthcare
    • 5.20.3.4 Home healthcare
  • 5.20.4 USER READINESS & IMPACT ASSESSMENT
    • 5.20.4.1 User readiness
      • 5.20.4.1.1 User A: Hospitals
      • 5.20.4.1.2 User B: Diagnostic centers
    • 5.20.4.2 Impact assessment
      • 5.20.4.2.1 User A: Hospitals
        • 5.20.4.2.1.1 Implementation
        • 5.20.4.2.1.2 Impact
      • 5.20.4.2.2 User B: Diagnostic centers
        • 5.20.4.2.2.1 Implementation
        • 5.20.4.2.2.2 Impact

6 SMART PILLS MARKET, BY TARGET AREA

• 6.1 INTRODUCTION
• 6.2 SMALL INTESTINE
  • 6.2.1 COMPLEXITIES IN DIAGNOSIS AND MONITORING OF SMALL INTESTINE TO AID ADOPTION OF SMART PILLS
• 6.3 LARGE INTESTINE
  • 6.3.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH
• 6.4 ESOPHAGUS
  • 6.4.1 HIGH PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND BARRETT'S ESOPHAGUS TO AUGMENT MARKET GROWTH
• 6.5 STOMACH
  • 6.5.1 IMPROVED DIAGNOSTIC ACCURACY AND EFFECTIVE PROXIMAL EXAMINATION SCOPE OF GASTRIC DISEASES TO DRIVE MARKET

7 SMART PILLS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 CAPSULE ENDOSCOPY
  • 7.2.1 INCREASED ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL BOWEL TUMORS TO DRIVE MARKET
• 7.3 PATIENT MONITORING
  • 7.3.1 NEED FOR STREAMLINED INTEGRATION OF INNOVATIVE SENSOR TECHNOLOGIES TO DRIVE MARKET
• 7.4 TARGETED DRUG DELIVERY
  • 7.4.1 SITE-SPECIFIC DRUG DELIVERY TO MINIMIZE DRUG DOSAGE AND REDUCE HEALTHCARE COSTS

8 SMART PILLS MARKET, BY DISEASE INDICATION

• 8.1 INTRODUCTION
• 8.2 OCCULT GASTROINTESTINAL BLEEDING
  • 8.2.1 IMPROVED DIAGNOSTIC ACCURACY TO FUEL UPTAKE OF SMART PILLS AS PATIENT-FRIENDLY ALTERNATIVE
• 8.3 CROHN'S DISEASE
  • 8.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPY TO BOOST ADOPTION OF SMART PILLS
• 8.4 CELIAC DISEASE
  • 8.4.1 RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET
• 8.5 SMALL BOWEL TUMORS
  • 8.5.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTICS TO PROPEL MARKET GROWTH
• 8.6 OTHER DISEASE INDICATIONS

9 SMART PILLS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS
  • 9.2.1 INCREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE TO BOOST ADOPTION OF SMART PILLS IN HOSPITALS
• 9.3 DIAGNOSTIC CENTERS
  • 9.3.1 BETTER PATIENT EXPERIENCE AND IMPROVED OPERATIONAL EFFICIENCY TO BOOST MARKET GROWTH
• 9.4 OUTPATIENT SETTINGS
  • 9.4.1 NEED FOR ACCESSIBLE AND COST-EFFECTIVE CARE TO SPUR MARKET GROWTH
• 9.5 OTHER END USERS

10 SMART PILLS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 US to dominate North American smart pills market during study period
  • 10.2.3 CANADA
    • 10.2.3.1 Rising incidence of IBD among geriatric population to propel market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Rising prevalence of Crohn's disease to aid market growth
  • 10.3.3 UK
    • 10.3.3.1 Increasing prevalence of bowel cancer and colitis to augment market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Favorable reimbursement coverage by government and third-party payers to aid market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Growing adoption of capsule endoscopy for gastrointestinal diseases to propel market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Rising demand for non-invasive diagnostics to fuel uptake of smart pills
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Increased prevalence of stomach cancer and favorable reimbursement scenario for capsule endoscopy to drive market
  • 10.4.3 CHINA
    • 10.4.3.1 Increasing geriatric population and rising incidence of gastric cancer to boost market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Rising incidence of IBD and growing adoption of capsule endoscopy to support market growth
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Favorable government policies and presence of universal health coverage to aid market growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Increased cancer awareness and favorable government initiatives to drive market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Increased focus on healthcare infrastructure development and high R&D investment to support market growth
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SMART PILLS MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Application footprint
    • 11.5.5.4 Target area footprint
    • 11.5.5.5 Disease indication footprint
    • 11.5.5.6 End-user footprint
    • 11.5.5.7 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 11.6.5.1 Detailed list of key startups/SME players
    • 11.6.5.2 Competitive benchmarking of key startups/SME players
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS
  • 11.9.2 DEALS
  • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 MEDTRONIC
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products/Services/Solutions offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product approvals & enhancements
      • 12.1.1.3.2 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 OLYMPUS CORPORATION
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products/Services/Solutions offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Other developments
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 CAPSOVISION, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products/Services/Solutions offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product approvals & enhancements
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 INTROMEDIC
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products/Services/Solutions offered
    • 12.1.4.3 MnM view
      • 12.1.4.3.1 Right to win
      • 12.1.4.3.2 Strategic choices
      • 12.1.4.3.3 Weaknesses & competitive threats
  • 12.1.5 JINSHAN SCIENCE & TECHNOLOGY
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products/Services/Solutions offered
    • 12.1.5.3 MnM view
      • 12.1.5.3.1 Right to win
      • 12.1.5.3.2 Strategic choices
      • 12.1.5.3.3 Weaknesses & competitive threats
  • 12.1.6 ANX ROBOTICS
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products/Services/Solutions offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches, approvals, and enhancements
  • 12.1.7 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products/Services/Solutions offered
  • 12.1.8 ETECTRX
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products/Services/Solutions offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product enhancements
      • 12.1.8.3.2 Deals
  • 12.1.9 BODYCAP
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products/Services/Solutions offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches
      • 12.1.9.3.2 Deals
  • 12.1.10 CHECK-CAP
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products/Services/Solutions offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product approvals
      • 12.1.10.3.2 Expansions
  • 12.1.11 SHANGXIAN MINIMAL INVASIVE INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products/Services/Solutions offered
• 12.2 OTHER PLAYERS
  • 12.2.1 VELOCE CORPORATION
  • 12.2.2 BIOCAM
  • 12.2.3 ENDIATX
  • 12.2.4 RF CO., LTD.
  • 12.2.5 CELERO SYSTEMS
  • 12.2.6 BIORA THERAPEUTICS, INC.
  • 12.2.7 INNURVATION
  • 12.2.8 RANI THERAPEUTICS
  • 12.2.9 MOTILIS MEDICA SA

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS